Clinical trial
A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract Cancers
NCT04910386 is registered in ClinicalTrials.gov with 3D Medicines (Sichuan) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract Cancers
- Lead sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 1, 2027
- Completion date
- December 31, 2029
- Enrollment
- 126 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.